Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Indication & Technology The global immune oncology assays market will witness a robust CAGR of 11.87%, valued at $3.84 billion in 2021, expected to appreciate and reach $11.74 billion by 2030, confirms Strategic Market Research. North America is expected to have the highest industry share, followed by Europe. Cancer treatment uses medications, surgery, radiation, and other therapies to cure. To monitor the efficacy and specificity of the cancer treatment, we use immuno-oncology Assays. An assay is a process of analyzing a substance to determine its composition or quality. Immunoassays are biochemical tests that use the binding ability of antibodies (immunoglobulin) and antigens (foreign substances) to detect and measure the concentration of target molecules. Types of Cancer Treatment Procedures - Chemotherapy: Chemotherapy uses drugs to kill cancer cells. Surgery: Surgery removes the cancer cells or as much cancer as possible. Radiation therapy: Uses high-powered energy beams (X-rays or protons) to kill cancer cells. Bone marrow transplant is a process in which healthy blood-forming stem cells are injected into the body to replace damaged bone marrow. Targeted drug therapy: Targets the changes that help cancer cells grow and spread. Radiofrequency ablation: Uses electrical energy to heat cancer cells, causing them to die. Cryoablation: The cancer cells are killed by repeatedly freezing and thawing the tissue using a thin needle (cryoprobe). Immuno-oncology: Immuno-oncology or immunotherapy (biological therapy) uses the body's immune system to fight cancer. Immuno-oncology manipulates the body's immune response to mount an attack against tumor cells. Benefits: Immuno-Oncology Assays Provide the Following Benefits: Monitoring: Enables Observation of immune responses to cancer cell models or patient samples. Tumor Cells characteristic: Characterize tumor cell proliferation, metastatic potential, and viability. Immune Cells Studies: Helps to identify, expand, and characterize immune cell populations, including T cell subsets. Co-culture Studies: Evaluates the impact and effect of numerous immune cells on tumor cells with apoptosis, killing, and phagocytosis assays. The benefits of immuno-oncology assays have led to long-lasting tumor regression where radiotherapy, surgery, chemotherapy, and targeted therapy are less effective. Application: The Applications of Immuno-oncology Assays are as Follows: CAR T-cell therapy- In chimeric antigen receptor (CAR) t-cell therapy, t-cells (immune cells, which are a type of white blood cell) are altered in the lab to fight cancer by destroying cancer cells. Stimulation of the immune cells - Monoclonal antibodies directly bind to the cancer cells to kill them by targeting specific receptors in the cells. Monoclonal antibodies are medicines that target checkpoint proteins. These drugs are called immune checkpoint inhibitors (checkpoint inhibitors). Safety and toxicity testing- To check the effectiveness of oncolytic viruses. Types of Immuno-oncology Assays: In vitro, PDX assays- Patient-derived xenograft (PDX) assays are models of cancer where the tissue or cells from a patient's tumor are implanted into an immune-deficient or humanized mouse. For in vitro cancer, cell-based assays are cost-effective in predicting mode of action, immunoreactivity, and efficacy. 3D tumor assays: The 3D tumor spheroid assay analyzes anti-cancer therapeutics' therapeutic effect and tumor-penetrating capacity. Immune-mediated tumor-killing assays: These assays test candidate compounds or antibodies for their immunomodulatory properties in enhancing the immune response against tumor cells. Tumor cell-based assays: The assays allow clients' immuno-oncology drug discovery by modeling their immunotherapies in tumor cell line assays. T cell-based assays-Elevate your drug discovery and develop cutting-edge immune-modulating therapies. Cytotoxic t-cells identify and target tumor cells for vandalizing it. Immuno-oncology therapeutics intend to mobilize, enhance and improve this process by either increasing the immune system's functionality (e.g., activation of tumor-specific t-cells) or counteracting the overall immune evasion of tumor cells. NK cell-mediated cytotoxicity assay- Natural killer cells assay that assesses your therapy's modulation of NK. Cell activity, providing critical data to progress your oncology programs. Macrophage assays: Macrophages are vital for preclinical drug screening of different tumor cells. This assay can evaluate the effect of anti-cancer therapy, such as immunotherapy, radiotherapy, and chemotherapy, on different tumor cells. Dendritic cell (DC) assays-Dendritic cells drive the t-cell response; they capture, process, and present intracellular and exogenous antigens on t-cells. Neutrophil functional assays: Neutrophils (a type of white blood cell) assist the body in fighting infection and can be detected by the shape of their nuclei and cytoplasmic granularity and flow cytometry. Fibroblast assays: Fibroblasts secrete collagen proteins that help maintain the structural framework of tissues. Used for screening of antimicrobial drugs. LDH-based cytotoxicity assay: An LDH cytotoxicity assay is a colorimetric assay that measures the stable, cytosolic lactate dehydrogenase (LDH enzyme). Apoptosis Assays: An apoptosis assay successfully detects and quantifies the cellular events associated with programmed cell death and cell surface exposure of phosphatidylserine (PS), including caspase activation and DNA fragmentation. T cell killing assay -A type of immune cell that can kill certain cells, including cancer cells, foreign cells, and cells infected by a virus. The APCs activate the t-cells in the lymph nodes and teach them to recognize the tumor cells. The t-cells travel through the blood vessels to reach the tumor, infiltrate it, recognize the cancer cells and kill them. B cell killing assay: Whereas t-cells physically attach to and attack cancer cells, B cells target them indirectly by producing molecules called antibodies (that can bind to tumor antigens). Complement-dependent cytotoxicity test: This assay uses lymphocyte target cells to detect and identify complement-fixing IgG and IgM antibodies that are present in a patient's serum post adding rabbit complement. Immune-cell killing assays: Immune cell killing allows for direct, multiplexed measurements of the immune cell-mediated killing of tumor cells. Key Industry Drivers - Rising Cases of Cancer Patients, Growing Adoption of Targeted Therapies, High Preference for Immunotherapies, And A High Success Rate Key Factors That Promote the Growth of The Immuno Oncology Assays Market Rising cases of Cancer Patients: The incidence of cancer is increasing rapidly, which is poised to drive the overall demand for an effective diagnostic method such as immunoassay. This growth is due to chronic and infectious disorders like the COVID-19 outbreak. Infectious disorders including SARS-CoV2 (COVID-19), Hepatitis B, C, HIV, Dengue, Malaria, Tuberculosis, and few among others, are on the rise. According to the International Agency for Research on Cancer's GLOBOCAN 2020, there were 19.3 million new cancer cases and over 10.0 million cancer deaths in 2020. Growing adoption of targeted therapies: The goal of targeted therapy is to find other characteristics of cancer cells. Scientists hunt for distinct variations between cancerous and non-cancerous cells. This data is utilized to develop a tailored medicine that attacks cancer cells while sparing healthy cells, resulting in fewer adverse effects. Monoclonal antibodies and anti-angiogenesis medicines are examples of modern targeted therapies. As a result, immuno-oncology tests have played a critical role in deciphering cancer markers and designing personalized Therapeutics. Preference to Immunotherapies: Patients increasingly prefer immunotherapies and immunodiagnostics due to the negative effects of radiation and chemotherapy and technological advancements in the immune-oncology assay. Antibodies raised against a single antigen or antigens linked with a specific analyte, infection, or clinical condition are used in immunodiagnostic assays. Immunotherapy is one of the cancer treatments which boosts the immune system's ability to fight cancer, infections, and other disorders. White blood cells, organs, and lymph tissue comprise this immune system. Checkpoint inhibitors, cytokines, and vaccination immunotherapy are the three types of Immunotherapies. Immunodiagnostic assays are diagnostic processes that include immune response products as part of the test. High Success rate: Accessibility and Accuracy: As the number of hospitals grows, so does the ease of access to treatments because they provide sensitive, specific results and are very simple to use. Immunoassays have become increasingly popular techniques for testing biologic analytes. Furthermore, some immunoassay procedures are quick, produce higher precision, and are very simple to automate, needing less hands-on involvement. According to the figures published in The Lancet on Performance characteristics of five immunoassays for SARS-CoV-2 accounted for sensitivity and specificity of at least 98%. Restraints - High Setup Cost and Procedural Delays High Setup Cost: The capital investments required to discover, develop, and validate biomarkers are very high. According to HTStec Limited's publication Automated Immunoassays Trends, immunoassay automation's median capital cost was $40-$60,000. Procedural Delays-Diagnostic manufacturers face major financial problems due to high drug attrition in clinical trials (almost 30% of medications fail in Phase III). To acquire regulatory permission for in vitro diagnostics (IVD), firms must complete Phase III clinical trials that rely on well-validated biomarker assays. A study by CenterWatch claims that only 6% of clinical trials are completed on time, and 80% of trials are delayed by at least one month. These delays affect study costs and sales, leading to potential losses of $600,000 to $8 million daily. Opportunities Emerging economies: Low regulatory obstacles, improved healthcare infrastructure, expanding patient population, and rising healthcare spending present considerable growth potential. Asia Pacific regulatory laws are more flexible and business-friendly than industrialized countries. In addition, rising competition in developed regions has prompted leading companies in the immuno oncology assays market to concentrate their efforts in emerging areas. Government Support-Surge in government initiatives in the field of biotech research is poised to create myriad opportunities in developing economies. The Federal Government regulates biotechnology products using health and environmental safety laws. Under these authorities, each agency has established regulations, policies, and guidance, as needed, to address various types of biotechnology products. For example, under the National Environmental Policy Act of 1969 (NEPA), the Government empowers the FDA and USDA to evaluate all major decisions that significantly influence the human environment. Automation: Technological development and advancement of the automated immuno-oncology assay is expected to create massive opportunities for industry growth throughout the forecast period Market Analysis Of Different Segments Covered in the Report Based on Product Reagents and Antibodies Instruments Software Consumables and Accessories Based on Technology Checkpoint Inhibitors Cytokines & Immunomodulators Monoclonal Antibodies Other Technologies Based on Indication Melanoma Colorectal Cancer Lung Cancer Other Cancers Based on End-Users Hospitals Clinics Cancer Research Centers Based on Application Research Applications Clinical Diagnostics Regional Coverage Analysis North America Asia- Pacific Europe North America Latin America The Middle East and Africa Segments Analysis & Insights Based on Product, the Consumables and Accessories segment held the greatest market due to the use of various types of kits, reagents, and devices for performing the assays. During the projected period, however, the software segment is expected to increase at the quickest rate. By Technology, the Monoclonal Antibodies segment dominates the industry. Monoclonal antibodies efficiently target specific cancer-affected cells and treat them while leaving healthy cells alone. Monoclonal antibodies are in high demand among cancer patients due to their minimal toxicity and adverse effects. According to recent findings published in the Frontiers in Medicine, most of the approved mAbs are used in oncology and immunology, while only a few are directed against infectious diseases. Further, the EMA and FDA have approved more than 100 monoclonal antibodies. Checkpoint inhibitors, on the other hand, are expected to be the fastest-growing segment due to expanding cancer treatment use. During the projection period, market participants' development strategies, such as collaborations for checkpoint inhibitor research and development, will likely increase demand for checkpoint inhibitors. Many different checkpoint inhibitors are now being studied due to their potential to improve the efficiency of immune responses. Checkpoint inhibitors prevent tumors from manipulating immunological checkpoints—the immune system's "brakes"—to suppress immune responses and protect themselves. The recent approval list by FDA has 7 checkpoint inhibitors to treat more than a dozen different types of cancer. By indication, the lung cancer segment captures Immuno oncology assays market share due to the high number of lung cancers worldwide. According to Global Burden of Disease (2017), lower respiratory infections are the 3rd leading cause of early death and will remain the same till 2040. By end-user, the hospital segment dominates the share due to increased hospital admissions related to cancer treatment. Furthermore, individuals prefer to obtain treatment for various types of cancer at a growing number of government and private facilities worldwide. The increasing penetration of hospitals worldwide and the increased use of cutting-edge medical technologies will likely fuel the segment's expansion. By Region, North America captures the largest market share due to an increase in funding by government agencies and a rise in focus on developing novel drugs and biomarkers in this region. In nations like the United States with established market economies, infectious diseases account for 4.2% of all disability-adjusted life years lost, whereas neoplastic and chronic diseases account for 81%, according to the estimates from the Global Burden of Disease Study. The Asia Pacific is poised to remain the fastest growing market due to an increase in the number of launches of Immuno-oncology assays, increasing adoption of targeted therapy, rising incidence of cancer, and increasing population in this region. According to the World Health Organization, ICU-acquired infections, such as UTIs and surgical-site wound infections, are two to three times greater in developing nations than in developed countries. Immuno Oncology Assays Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 3.84 Billion The revenue forecast in 2030 USD 11.74 Billion Growth rate CAGR of 11.87% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Technology, By Indication, By End-user, and By Region. By Product Reagents and Antibodies, Instruments, Software, Consumables, and Accessories. By Technology Monoclonal Antibodies, Cytokines & Immunomodulators, Checkpoint Inhibitors, and Other Technologies. By Indication Lung Cancer, Colorectal Cancer, Melanoma, and Other Cancers By End-user Hospitals, Clinics, and Cancer Research Centers. By Region Europe, Asia-Pacific, North America, Middle-East and Africa, and South America. Country Scope Mexico, Canada, US, Germany, UK, France, Japan, India, China, etc. Company Usability Profiles Agilent Technologies, Bio-Rad Laboratories, Charles River Laboratories, F. Hoffmann-La Roche, Illumina, PerkinElmer, Qiagen N.V., Sartorius Ag., and Thermo Fisher Scientific. Immuno Oncology Assays Market Competitive Landscape Analysis The report presents the competitive landscape analysis, bringing to light the top performing competitors operating in the industry. The comparison is based on initiatives, R&D investment, production analysis, value chain optimization, overall revenue generation, market share financials, company strengths and weaknesses, company overview, global presence, production sites and facilities, production capacity, potential, and other variables. Illumina, Inc. Qiagen Nv. Charles River Laboratories, Inc. F. Hoffmann-La Roche Ltd. Agilent Technologies, Inc. Nanostring Technologies, Inc. Perkinelmer, Inc. Bio-Rad Laboratories, Inc. Thermo Fisher Scientific, Inc. Sartorius Ag Recent Developments: On 7th July 2022, Rvyu Therapeutics & Exelixis collaboratively issued a license agreement to develop a STING Agonist Based Targeted Cancer Therapy. This cancer immunotherapy based on immune checkpoint blockade will immensely help modify the various carcinoma treatment methods across the several types of malignant tumors. On 15th June 2022, Agilent Technologies revealed that it had successfully received the MFDS approval for its PD L1 IHC 22C3 PharmDx to detect the patients having NSCLC (Non-Small Cell Lung Cancer) who required 1st line monotherapy with KEYTRUDA on the platform of Dako Omnis. This was marked as the 3rd approval that Agilent received from MFDS to enable the patient’s access to the various targeted immunotherapies to improve patient outcomes. On 10th March 2022, Explicyte and Domain Therapeutics created an immuno-oncology partnership. Explicyte, a leader in immuno-oncology (IO) and multiparametric target identification, and Domain Therapeutics, a biopharmaceutical company targeting G Protein-Coupled Receptors (GPCRs) in IO, have announced the signing of a collaboration agreement. The two companies will use their knowledge to identify GPCR targets and associated biomarkers to uncover and develop novel IO therapy regimens. Financial information is unavailable. In March 2022, The US FDA approved StemCyte's biologics license application for its allogeneic umbilical cord hematopoietic progenitor cell product "HPC-Cord Blood." The FDA received the BLA for the "HPC-Cord Blood" product on January 7th, 2022, and StemCyte was advised on March 8th, 2022, that the submission was acceptable to join the biologics license quality review process. In February 2021, Opna Immuno-Oncology SA, a pharmaceutical business, announced that it would raise funds through venture capital. The company plans to raise money by selling stock to investors. Opna Immuno-Oncology SA (Opna Immuno-Oncology) is a biotechnology company focused on cancer immunotherapy. The business plans to develop cancer immunotherapy that will target cancer cells that have developed resistance to current treatments. In November 2020, CAIAC Fund Management AG agreed to purchase a 51% stake in Helix Immuno-Oncology SA, a developer of innovative products based on proprietary technologies for use in cancer immunotherapy, for gross proceeds of up to PLN6.7 million from Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique immuno-oncology therapies. Various Products that Key Market Leaders Develop: Product Function Key players ProcartaPlex Panel Enables cancer research by analyzing 14 protein targets using Luminex xMAP technology. Thermo Fisher Scientific Elecsys Anti-p53 Immunoassay to diagnose throat, bowel, and breast cancers in patients. Roche CELESTIAL Visualize cellular responses such as cell proliferation, cell viability, and the ability to distinguish between different modes of cell death. Enzo Life Sciences Ipsogen JAK2 The kit is for real-time PCR on the Rotor-Gene Q and other real-time PCR instruments. QIAGEN Frequently Asked Question About This Report What are the immuno oncology assays market growth? The global immuno oncology assays market is expected to grow at a compound annual growth rate (CAGR) of 11.87 % from 2021 to 2030 to reach USD 11.74 Billion by 2030. What are the major applications of market? Cytokine Profiling, Immunogenicity testing, Live-cell analysis of cancer cells for precision cancer treatment. Other In vitro cancer cell-based assays include Cell Viability Assays, Cell Invasion Assays, Cell Migration Assays, Cell Proliferation Assays, Cytotoxicity Assays and Cell Death Assays (Necrosis, Autophagy and Apoptosis Assays). How big is the immuno oncology assays market? The global immuno oncology assays market size was $ 3.84 Bn in 2021 and is predicted to reach $ 11.74 Bn by 2030, with a CAGR of 11.87 %. What are the recent trends affecting the immuno-oncology assays market? Immuno-oncology assays market trends suggest a high growth rate due to the COVID-19 outbreak, rising incidence and prevalence of cancer, and the growing adoption of targeted therapy. Other In vitro cancer cell-based assays that are gaining attention are Cell Viability Assays, Cell Invasion Assays, Cell Migration Assays, Cell Proliferation Assays, Cytotoxicity Assays, Antibody-mediated cytotoxicity assay, antibody-dependent cellular phagocytosis, MTT assay and Cell Death Assays (Necrosis, Autophagy and Apoptosis Assays) Sources https://pubmed.ncbi.nlm.nih.gov/33538338/ https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext https://www.ddw-online.com/.well-known/captcha/?r=%2Fmedia%2F32%2Fimmunoassay-automation.pdf https://www.frontiersin.org/articles/10.3389/fimmu.2021.626616/full https://www.healthdata.org/gbd/2019 https://apps.who.int/iris/bitstream/handle/10665/80135/9789241501507_eng.pdf 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Immuno Oncology Assays Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Immuno Oncology Assays Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Indication Business Analysis 4.4.1 market, By Indication, 2021 - 2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021 - 2030 (USD Million) 4.6 Technology Business Analysis 4.6.1 market, By Technology, 2021 - 2030 (USD Million) 4.7 End-user Business Analysis 4.7.1 market, By End-user, 2021 - 2030 (USD Million) 4.8 Product Analysis 4.8.1 market, By Product, 2021 - 2030 (USD Million) 4.9 Value Chain Analysis 4.10 Market Variable Analysis 4.10.1 Market Drivers Analysis 4.10.2 Market Restraints Analysis 4.11 Business Environment Analysis Tool 4.11.1 market PEST analysis 4.11.2 market Porter’s analysis 4.12 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2021) 5.11.2. Trends in End-user (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Indication 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Indication Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Lung Cancer 7.3.1. Lung Cancer market, 2021 - 2030 (USD Million) 7.4. Colorectal Cancer 7.4.1. Colorectal Cancer market, 2021 - 2030 (USD Million) 7.5. Melanoma 7.5.1. Melanoma market, 2021 - 2030 (USD Million) 7.6. Breast Cancer 7.6.1. Breast Cancer market, 2021 - 2030 (USD Million) 7.7. Bladder Cancer 7.7.1. Bladder Cancer market, 2021 - 2030 (USD Million) 7.8. Other Cancers 7.8.1. Other Cancers market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Research Applications 8.3.1. Research Applications market, 2021 - 2030 (USD Million) 8.4. Clinical Diagnostics 8.4.1. Clinical Diagnostics market, 2021 - 2030 (USD Million) 9. Market: By Technology Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Monoclonal Antibodies 9.3.1. Monoclonal Antibodies market, 2021 - 2030 (USD Million) 9.4. Cytokines & Immunomodulators 9.4.1. Cytokines & Immunomodulators market, 2021 - 2030 (USD Million) 9.5. Checkpoint Inhibitors 9.5.1. Checkpoint Inhibitors market, 2021 - 2030 (USD Million) 9.6. Immunoassay 9.6.1. Immunoassay market, 2021 - 2030 (USD Million) 9.7. PCR 9.7.1. PCR market, 2021 - 2030 (USD Million) 9.8. NGS 9.8.1. NGS market, 2021 - 2030 (USD Million) 9.9. Flow Cytometry 9.9.1. Flow Cytometry market, 2021 - 2030 (USD Million) 9.10. Other Technologies 9.10.1. Other Technologies market, 2021 - 2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021 - 2030 (USD Million) 10.4. Clinics 10.4.1. Clinics market, 2021 - 2030 (USD Million) 10.5. Clinical Laboratories 10.5.1. Clinical Laboratories market, 2021 - 2030 (USD Million) 10.6. Cancer Research Centers 10.6.1. Cancer Research Centers market, 2021 - 2030 (USD Million) 11. Market: By Product Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Reagents and Antibodies 11.3.1. Reagents and Antibodies market, 2021 - 2030 (USD Million) 11.4. Instruments 11.4.1. Instruments market, 2021 - 2030 (USD Million) 11.5. Software 11.5.1. Software market, 2021 - 2030 (USD Million) 11.6. Consumables and Accessories 11.6.1. Consumables and Accessories market, 2021 - 2030 (USD Million) 12. Market: Regional Outlook 12.1 North America 12.1.1. North America market, By Indication, 2021 - 2030 (USD Million) 12.1.2. North America market, By Application, 2021 - 2030 (USD Million) 12.1.3. North America market, by End-user, 2021 - 2030 (USD Million) 12.1.4. North America market, by Specimen Type, 2021 - 2030 (USD Million) 12.1.5. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Indication, 2021 - 2030 (USD Million) 12.1.4.1.2. U.S. market, By Application, 2021 - 2030 (USD Million) 12.1.4.1.3. U.S. market, by End-user, 2021 - 2030 (USD Million) 12.1.4.1.4. U.S. market, by Specimen Type, 2021 - 2030 (USD Million) 12.1.4.1.5. U.S. market, by Country, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Indication, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Application, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by End-user, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Indication, 2021 - 2030 (USD Million) 12.2.2. Europe market, By Application, 2021 - 2030 (USD Million) 12.2.3. Europe market, by End-user, 2021 - 2030 (USD Million) 12.2.4. Europe market, by Specimen Type, 2021 - 2030 (USD Million) 12.2.5. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Indication, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Application, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by End-user, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Indication, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by End-user, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Indication, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Application, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by End-user, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Indication, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Application, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by End-user, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Indication, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 12.3.3. Asia Pacific market, by End-user, 2021 - 2030 (USD Million) 12.3.4. Asia Pacific market, by Specimen Type, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Indication, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Application, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by End-user, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Indication, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Application, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by End-user, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Indication, 2021 - 2030 (USD Million) 12.3.4.3.2. Japan market, By Application, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by End-user, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Indication, 2021 - 2030 (USD Million) 12.3.4.4.2. South Korea market, By Application, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by End-user, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Indication, 2021 - 2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Indication, 2021 - 2030 (USD Million) 12.4.2. Latin America market, By Application, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by End-user, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by product, 2021 - 2030 (USD Million) 12.4.5. Latin America market, by Technology, 2021 - 2030 (USD Million) 12.4.6. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Indication, 2021 - 2030 (USD Million) 12.4.4.1.2. Brazil market, By Application, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by End-user, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Indication, 2021 - 2030 (USD Million) 12.4.4.2.2. Mexico market, By Application, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by End-user, 2021 - 2030 (USD Million) 12.4.4.3. Rest of Latin America 12.4.4.3.1. Rest of the Latin America market, By Indication, 2021 - 2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Application, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Indication, 2021 - 2030 (USD Million) 12.5.2. MEA market, By Application, 2021 - 2030 (USD Million) 12.5.3. MEA market, by End-user, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Technology, 2021 - 2030 (USD Million) 12.5.5. MEA market, by Product, 2021 - 2030 (USD Million) 12.5.6. MEA market, by Region, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 Agilent Technologies, Inc 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Indication Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Bio-Rad Laboratories, Inc 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Indication Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. Charles River Laboratories, Inc 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Indication Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. F. Hoffmann-La Roche Ltd 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Indication Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Illumina, Inc 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Indication Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. Nanostring Technologies, Inc 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Indication Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Perkinelmer, Inc 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Indication Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Qiagen Nv 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Indication Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. Sartorius Ag 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Indication Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. Thermo Fisher Scientific, Inc 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Indication Portfolio Analysis 13.10.4. Business Strategy & Recent Development List of Tables (69 Tables) TABLE 1. MARKET, By Indication, 2021-2030 (USD Million) TABLE 2. Lung Cancer, BY REGION, 2021-2030 (USD Million) TABLE 3. Colorectal Cancer, BY REGION, 2021-2030 (USD Million) TABLE 4. Melanoma, BY REGION, 2021-2030 (USD Million) TABLE 5. Breast Cancer, BY REGION, 2021-2030 (USD Million) TABLE 6. Bladder Cancer, BY REGION, 2021-2030 (USD Million) TABLE 7. Other Cancers, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET, By Application, 2021-2030 (USD Million) TABLE 9. Research Applications, BY REGION, 2021-2030 (USD Million) TABLE 10. Clinical Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 12. Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 13. Clinics, BY REGION, 2021-2030 (USD Million) TABLE 14. Cancer Research Centers, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET, By Technology, 2021-2030 (USD Million) TABLE 16. Monoclonal Antibodies, BY REGION, 2021-2030 (USD Million) TABLE 17. Cytokines & Immunomodulators, BY REGION, 2021-2030 (USD Million) TABLE 18. Checkpoint Inhibitors, BY REGION, 2021-2030 (USD Million) TABLE 19. Immunoassay, BY REGION, 2021-2030 (USD Million) TABLE 20. PCR, BY REGION, 2021-2030 (USD Million) TABLE 21. NGS, BY REGION, 2021-2030 (USD Million) TABLE 22. Flow Cytometry, BY REGION, 2021-2030 (USD Million) TABLE 23. Other Technologies, BY REGION, 2021-2030 (USD Million) TABLE 24. MARKET, By Product, 2021-2030 (USD Million) TABLE 25. Reagents and Antibodies, BY REGION, 2021-2030 (USD Million) TABLE 26. Instruments, BY REGION, 2021-2030 (USD Million) TABLE 27. Software, BY REGION, 2021-2030 (USD Million) TABLE 28. Consumables and Accessories, BY REGION, 2021-2030 (USD Million) TABLE 29. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 30. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 31. NORTH AMERICA MARKET, By Indication, 2021-2030 (USD Million) TABLE 32. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 33. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 34. NORTH AMERICA MARKET, BY Product, 2021-2030 (USD Million) TABLE 35. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 36. EUROPE MARKET, By Indication, 2021-2030 (USD Million) TABLE 37. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 38. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 39. EUROPE MARKET, BY Product, 2021-2030 (USD Million) TABLE 40. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 41. ASIA-PACIFIC MARKET, By Indication, 2021-2030 (USD Million) TABLE 42. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 43. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 44. ASIA-PACIFIC MARKET, BY Product, 2021-2030 (USD Million) TABLE 45. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 46. LAMEA MARKET, By Indication, 2021-2030 (USD Million) TABLE 47. LAMEA MARKET, By Technology, 2021-2030 (USD Million) TABLE 48. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 49. LAMEA MARKET, BY Product, 2021-2030 (USD Million) TABLE 50. Agilent Technologies, Inc: COMPANY SNAPSHOT TABLE 51. Agilent Technologies, Inc: OPERATING SEGMENTS TABLE 52. Bio-Rad Laboratories, Inc: COMPANY SNAPSHOT TABLE 53. Bio-Rad Laboratories, Inc: OPERATING SEGMENTS TABLE 54. Charles River Laboratories, Inc: COMPANY SNAPSHOT TABLE 55. Charles River Laboratories, Inc: OPERATING SEGMENTS TABLE 56. F. Hoffmann-La Roche Ltd: COMPANY SNAPSHOT TABLE 57. F. Hoffmann-La Roche Ltd: OPERATING SEGMENTS TABLE 58. Illumina, Inc: COMPANY SNAPSHOT TABLE 59. Illumina, Inc: OPERATING SEGMENTS TABLE 60. Nanostring Technologies, Inc: COMPANY SNAPSHOT TABLE 61. Nanostring Technologies, Inc: OPERATING SEGMENTS TABLE 62. Perkinelmer, Inc: COMPANY SNAPSHOT TABLE 63. Perkinelmer, Inc: OPERATING SEGMENTS TABLE 64. Qiagen Nv: COMPANY SNAPSHOT TABLE 65. Qiagen Nv: OPERATING SEGMENTS TABLE 66. Sartorius Ag: COMPANY SNAPSHOT TABLE 67. Sartorius Ag: OPERATING SEGMENTS TABLE 68. Thermo Fisher Scientific, Inc: COMPANY SNAPSHOT TABLE 69. Thermo Fisher Scientific, Inc: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Indication-Based Estimation Figure 6 Top 10 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Immuno Oncology Assays Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Immuno Oncology Assays Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Indication, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Technology, 2019 vs. 2025 (USD Million) Figure 16 Geographical Snapshot of the Market Figure 17 Lung Cancer to Witness Higher CAGR in Indication Segment during Forecast Period. Figure 18 Hospitals to Witness Higher CAGR in End-user Segment during Forecast Period. Figure 19 Monoclonal Antibodies to Witness Higher CAGR in Technology Segment during Forecast Period. Figure 20 Consumables and Accessories to Witness Higher CAGR in Product Segment during Forecast Period. Figure 21 Research Applications to Witness Higher CAGR in the Application Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview